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Abstract
Glyco-gold nanoparticles combine in a single entity the peculiar properties of gold nanoparticles with the biological activity of
carbohydrates. The result is an exciting nanosystem, able to mimic the natural multivalent presentation of saccharide moieties and
to exploit the peculiar optical properties of the metallic core. In this review, we present recent advances on glyco-gold nanoparticle
applications in different biological fields, highlighting the key parameters which inspire the glyco nanoparticle design.
Introduction
Carbohydrates are well recognized as crucial biomolecules for
their capability to produce an enormous number of biocodes
which are translated into their ability to promote or suppress a
plethora of biological events [1]. Nevertheless, carbohydrates
interact with their ligands in a very weak manner, so much faint
that nature found in the multi-presentation (the so called “glyco-
calix”) a solution to have efficient carbohydrate interactions. In
fact, the sum of binding affinities for single and isolated interac-
tion is ever lower than those measured when a glyco-multiva-
lent presentation is exploited [2]. Following nature’s design,
carbohydrate multivalent systems are, at the present time, the
most common strategy used to study weak carbohydrate–carbo-
hydrate or carbohydrate–protein interactions and the resulting
biological processes [3,4].
The increasing ability to manipulate material at the nanosize
allowed the development of many glyco nanoparticles helpful in
a wide range of applications, from the drug delivery to the
imaging [5-7]. Among the large number of nanomaterials, gold
is one of the main exploited scaffolds for producing glyco nano-
particles [3,4]. First of all, gold is an extremely inert and
biocompatible material. At nanosize, gold nanoparticles
(AuNPs) are characterized by unique optical features which
result extremely useful in many diagnosis and affinity studies or
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Figure 1: Schematic overview on the glyco-gold nanoparticles synthetic approaches.
protocols. Moreover, gold can be easily and covalently deco-
rated on its surface by exploiting the strong soft–soft interac-
tion between a Au atom and sulfur [8]. Therefore, glyco-gold
nanoparticles (GAuNPs) represent a smart, multimodal and
versatile nanoplatform to develop carbohydrate-based nanotech-
nology and nanomedicine systems.
The present review focuses its attention only toward the synthe-
sis of gold-based nanoparticles coated with carbohydrates. A
first introduction related to the main protocols to produce glyco-
gold nanoparticles is followed by a section where the main pa-
rameters which should be taken into account for designing the
best performing nanosystem are discussed. Then, three sections
summarize the achievements and ongoing researches published
in the last four years, from 2013 to 2016 with a special focus on
glyco-gold nanoparticle applications (in biosensing field, as
drug carriers or contrast agents and as effective tool in the
immunological field).
Review
Synthesis of glyco-gold nanoparticles
Despite the great inertness of this noble metal, Au can form
stable bonds with sulfur-containing compounds (i.e., thiols or
disulfides) [9,10] and it is possible to easily and robustly func-
tionalize AuNPs with organic molecules. The synthetic ap-
proaches to GAuNPs can be classified into three major cate-
gories (Figure 1).
The first one consists in a one-step preparation of ultrasmall
spherical gold nanoparticles coated with a thio-glucoside [4,11-
16]. The process, developed in 2001 by Penadès and co-workers
[15] is a modified Brust–Shiffrin method [17], based on the in
situ Au3+ reduction by means of NaBH4 in the presence of
thiol-ending neoglycoconjugates. Following this approach, a
rapid synthesis of AuNPs characterized by elevated glycan den-
sity on the NP surface and a 1–10 nm diameter range can be ob-
tained [4]. Moreover, this synthetic procedure allows to intro-
duce different types of carbohydrates and other ligands (i.e.,
polyethylene chains, lipids, peptides, DNA, RNA or fluores-
cent dyes) in controlled ratios [4]. A modification of this tech-
nique consists in the application of the “thiol for thiol” ligand
exchange method, which allows the superficial diversification
by introducing small amounts of different ligands after the
AuNP synthesis [11,12,18]. Recently, the Seeberger group re-
ported a straightforward one-pot method to prepare glucose-
stabilized ultrasmall AuNPs, by simply mixing at room temper-
ature Au3+ salts and thio-glucoside as reducing and stabilizing
agents, without the addition of NaBH4 [19].
The two-step synthetic procedure consists in the initial synthe-
sis of AuNPs stabilized by temporary compounds (i.e., citrates,
amines or phosphines), followed by the ligand exchange
protocol to introduce the thiolated saccharide molecules [20-
22]. In this frame, the Turkevich method [23] is the most
common protocol to produce citrate-capped spherical nanoparti-
cles, with diameter size between 10 and 50 nm. Noteworthy, by
employing surfactant or templating agents (i.e, AgNO3 or cetyl-
trimethylammonium bromide, CTAB), a control over the core
morphology can be implemented with this methodology, as re-
ported for the synthesis of mannose and galactose functionali-
zed nanorods and nanostars [24] or glucosamine-coated nano-
star AuNPs [22]. Respect to other methodologies, the main
drawbacks of this protocol are the longer reaction times
(12–24 hours), the lower glycan loading and the difficulty for a
fine control of the organic shell composition.
The last category collects all the protocols based on chemical
conjugations of sugar residues to ligands displayed on the metal
surface of pre-formed AuNPs. Despite the longer times re-
quired for the NP synthesis and the first coating, the main
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Figure 2: Glyco-gold nanoparticles: metallic core and glyco-coating contribute to the production of the versatile glyco-nanomaterials.
advantages of this approach are the use of a lower amount of
precious sugar residues and the possibility to exploit different
orthogonal surface functionalizations. Reactions employed for
this purpose (i.e., click reaction, amidation, conjugation via
carbonyldiimidazol and perfluorophenyl azide (PFPA) photo-
coupling) have to be compatible with water, the common medi-
um for AuNP preparation [25-29]. One example of the three-
step approach was described by Tian and co-workers [28].
AuNPs were firstly coated by a monolayer of dithiol-cyclooc-
tyne spacer. Then, the alkyne moiety reacted with mannosyl
azide through a copper-free strain-promoted alkyne-azide cyclo-
addition (SPAAC), affording the GAuNPs. Alternatively, Yan
and co-workers developed a three-step photocoupling proce-
dure for the immobilization of carbohydrates on the nanoparti-
cles surface [27]. The AuNPs were firstly coated with a PFPA-
thiol monolayer via a ligand-exchange reaction, then carbo-
hydrates were immobilized by means of a photocoupling reac-
tion.
Glyco-gold nanoparticles: design and struc-
tural properties
GAuNPs are constituted by two main entities, the metallic core
and the organic surface (i.e., mono- oligo- and polysaccharides).
The features of these entities are tightly related to their applica-
tion and effectiveness (Figure 2). Therefore, a careful design of
GAuNP is required to obtain the best performing system.
Gold core: optical properties
AuNPs, widely employed for biomedical applications, are char-
acterized by inert nature, resisting to air oxidation and corro-
sion [30]. This chemical non-reactivity and inertness make
AuNPs an outstanding candidate for the development of in vitro
and in vivo devices [31,32]. Furthermore, in vitro and in vivo
short term reduced toxicity of AuNPs has been widely docu-
mented [10,33-38]. AuNPs own a number of peculiar optical
properties, strongly dependent on the size and the morphology
of the metallic core. When AuNP dimension is comparable to
the gold Fermi wavelength, the nanoparticles acquire photolu-
minescence properties [31]. These small clusters typically
present a diameter between 0.5 and 2 nm. When clusters are
bigger, they do not present fluorescent emission but they show a
localized surface plasmon resonance (LSPR) around 520 nm.
This phenomenon consists in a collective oscillation of the free
electrons of the metal, induced by the light impinging on the
AuNPs [31,39]. The AuNP surface plasmon resonance is de-
pendent upon a vast number of parameters like size, shape, mor-
phology and environment surrounding AuNPs [40]. By control-
ling these parameters, it is possible to tune the LSPR peak
through the visible and near IR spectra. As effect of the LSPR
process, the incident light is strongly attenuated and intense
electric fields are generated in the proximity of the AuNP sur-
face. These electric fields are of great interest because they can
be employed to enhance the intensity of Raman signals close to
the NP surface, widely explored in biomedical diagnostics (sur-
face enhanced Raman spectroscopy, SERS). This effect is even
more intense when the nanoparticles possess an irregular shape,
generating an anisotropic distribution of the magnetic field [41].
AuNP optical properties have been widely exploited in the
design of GAuNPs with interesting applications such as the
colorimetric biosensors. Based on the LSPR phenomenon, the
controlled aggregation and de-assembling of AuNPs is re-
flected in a detectable variation of the colloidal solution color.
Therefore, several biosensors for the detection of proteins [42],
lectin [25,27,43], cancer biomarkers [28] and viruses [44,45]
were developed. Photoluminescence properties of ultrasmall
gold nanoclusters and nanodots have been exploited to detect
Escherichia coli (a bacteria containing mannose-binding recep-
tors) [46] and thyroglobulin in serum [47] and to study the
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internalization pathway in dendritic cells, employing confocal
laser microscopy (CLSM) and flow cytometry [48]. Moreover,
even techniques based on light scattering, like dark field
microscopy (DFM), resulted convenient for the biosensing ap-
plication, considering that the light scattered by a single AuNP
can be about 1 million times more intense than the fluorescence
emitted by a dye [49,50].
Gold core: the size and the shape role
AuNP core dimension and shape are important parameters to
take into consideration for the multivalent carbohydrate presen-
tation [51-53]. In fact, a denser ligand packing can be obtained
when NP dimensions are bigger and the curvature radius is
reduced. This observation was already highlighted by Lin et al.,
during their studies on the interactions among Shiga toxins and
multivalent GAuNPs [52]. The authors, comparing the affini-
ties of 4, 13 and 20 nm AuNPs, demonstrated that, when the di-
ameter grows and the surface becomes flatter, the interaction
with the proteins binding sites is facilitated. Besides the AuNP
size, the NP shape can affect the effectiveness of active mole-
cules displayed on the metallic surface. In particular, an in vitro
study performed by Mitragotri and co-workers reported that the
endothelial targeting specificity could be enhanced by modu-
lating the NP shape. By using a microfluidic synthetic vascular
network the authors demonstrated that rod-shaped NPs exhibit
elevated specific accumulation in comparison to spherical ones
[54]. Recently, Kikkeri et al. published two interesting papers
evaluating the impact of the AuNP shape on the carbohydrate
presentation and activity [24,55]. In the first work the authors
reported the employment of GAuNPs for the bacterial recogni-
tion and bacterial infection inhibition. Three different morphol-
ogies of AuNPs (sphere, rod and star-like NPs) coated with
galactose and mannose derivatives were employed for the quan-
tification of their binding affinity to E. coli, suggesting that each
shape could induce a different bacterial adhesion. Indeed, gold
nanorods  presented  a  bac ter ia  de tec t ion  l imi t  of
0.03 ± 0.01 µg/mL, 80-folds more sensitive than spherical and
star shaped AuNPs. This discrepancy has been ascribed to the
difference in the relative amount of mannose involved in the
NP-bacteria interaction. The same group in 2016 investigated as
well the effect of the AuNP morphology on carbohydrate–pro-
tein interactions in mammalian cells. In particular, the authors
studied the shape-dependent uptake of mannose- and galactose-
functionalized AuNPs in different cancer cells. By employing
an enzyme-linked immunosorbent assay (ELISA), the selec-
tivity and sensitivity of the binding were demonstrated to be de-
pendent on the sugar nature and on the NP morphology. The
cellular uptake experiments on HeLa, HepG2 and MDA-MB-
231 cells showed in fact an higher clathrin-mediated internaliza-
tion for rod-shaped AuNPs in comparison to spherical and star-
shaped AuNPs.
Saccharidic functionalization: the coating density
Besides the inorganic core, the surrounding organic shell plays
a crucial role in GAuNP chemical-physical properties. The
organic functionalization, in fact, impart the stealth ability and
biocompatibility of the nanomaterials. Moreover, when the
metallic surface is decorated with an active target, the GAuNPs
can act as a smart probe, even exploiting the multivalent effect.
Several studies were focused on the investigation of synthetic
techniques to improve saccharide density on the nanomaterial
surface [45,56-58]. Prosperi and co-workers coated dode-
canthiol AuNPs with manno-calixarenes exploiting hydro-
phobic interactions, obtaining an efficient targeting against
cancer cells [56]. Similarly, a reversible addition−fragmenta-
tion chain transfer (RAFT) polymerization approach has been
exploited for the preparation of “multicopy–multivalent”
AuNPs, decorated with complex glycan structures. The high
degree of ramification resulted in a strong selective recognition
[57,58] with the possibility to modulate the glycosylic loading.
Even if the carbohydrate loading is important, not always a high
carbohydrate density is reflected in an improved affinity and it
depends on the biological event observed [18,59-64]. For exam-
ple, in the case of carbohydrate−protein interactions, the carbo-
hydrate disposition on the NP surface is more important than
the loading of the active molecule. Proteins, like lectins, are
characterized by different subunits possessing characteristic dis-
tances between the active pockets, so a controlled carbohydrate
density can result in a better presentation of the molecules [60].
Saccharidic functionalization: the importance of the
linker
The linker employed to space glycans from the Au surface is
another fundamental factor to take into consideration in GAuNP
design. Generally, the majority of the spacers are thiol-linkers,
exploiting the strong soft–soft interaction between gold and
sulfur. The spacer has the crucial role to stabilize GAuNPs in
the surrounding media, which is fundamental in the case of
colorimetric bioassays where the NP colloidal stability can
strongly influence the state of aggregation and, consequently,
the analysis results [43,65,66]. Woods et al., in a recent paper,
performed a computational study to evaluate the role of the
spacer in the glycan–protein interaction [67]. The authors
considered different types of spacer in terms of chemical struc-
ture, length and rigidity and demonstrated that longer linkers
resulted as the best performing ones, giving a better access to
the protein pocket. Furthermore, they showed that rigid spacers
could hinder the binding, by creating unfavorable interactions
with the protein surface, while flexible spacers resulted in a
better carbohydrate presentation and subsequent interaction
with the target. Schlecht and co-workers experimentally demon-
strated that the binding selectivity of GAuNPs toward P-selectin
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was affected not only by the spacer length but also by the pres-
ence of amide bonds next to the protein pocket [51].
Saccharidic functionalization: colloidal and stealth
ability
GAuNP colloidal stability and stealth abilities in biological
media and in intracellular environment is a fundamental issue
for the efficacy of these nanomaterials [68]. The use of stealth
coatings is an effective strategy to decrease or inhibit the non-
specific interaction with plasma proteins (the so called “protein
corona”), that can modify GAuNP biological identity, affecting
aggregation, and cellular uptake [69-71]. Moya and co-workers
deeply studied the intracellular dynamics and aggregation of
glucose-AuNPs by employing fluorescence correlation spec-
troscopy (FCS) [12]. They demonstrated that GAuNPs were
ubiquitous distributed inside the cell as single NP or small
aggregates, suggesting a strong intracellular stability. Liz-
Marzan et al. assessed the ability of glycan ligands to reduce the
protein corona formation around rod-shaped AuNPs [71].
Lactose- and polyethylene glycol (PEG)-functionalized gold
nanorods demonstrated similar ability in reducing the interac-
tion with proteins, when compared to citrate-AuNPs. Moreover,
comparing the macrophage NP uptake, the authors demon-
strated that the lactose shell can prevent phagocytosis more effi-
ciently than PEG coating.
A deep knowledge of any aspect which can influence the
GAuNP behavior is important to drive the correct design of the
nanosystem and is strongly related to the final bioapplication.
Glyco-gold nanoparticles as nanosensors
GAuNPs are able to create supramolecular networks by inter-
acting with proteins, enzymes or other carbohydrates and this
interaction is reflected in a measurable shifting of the LSPR
band, due to the aggregation of the metall ic  NPs.
Carbohydrate–carbohydrate interactions (CCIs), generally char-
acterized by KD values in the millimolar range, are very diffi-
cult to detect. Updated data confirm the crucial role of these
bindings in the regulation of many cellular processes [72], how-
ever, researches related to the use of carbohydrate-coated gold
nanoparticles to investigate CCIs, are still in their infancy and
will be not detailed in the present review [73,74]. On the con-
trary, a vast number of papers reported the use of glyco-gold
nanoparticles as smart nanomaterial, able to recognize and
interact with proteins, viruses and peptide hormones.
Detection of carbohydrate–protein interactions
Carbohydrate–protein interactions have a crucial role in many
pathological and physiological cellular functions, acting as a
main process correlated with a large number of biological
events, such as inflammations, cancer metastasis, fertility, etc.
[75-77]. Lectins are the most diffused class of proteins which
recognize carbohydrate ligands and they are widely studied to
develop systems able to detect lectin–carbohydrate interactions.
Yan et al. exploited the use of gold nanoparticles to recognize
and differentiate lectins by capping gold surface with eleven
different carbohydrate ligands [78]. To achieve their goal, the
authors treated GAuNPs with lectins and used the linear
discriminant analysis (LDA) to analyze the LSPR shifts and
recognize the lectins in a complex sample. A similar approach,
based on LDA, has been employed by Gibson et al. to provide
discrimination among legume lectins [79]. In their paper, the
authors synthesized eleven GAuNPs, by tuning a heterogen-
eous coatings using only two 2-amino-2-deoxysugars (galac-
tosamine and mannosamine). By means of this approach, and
limiting the carbohydrate synthetic efforts, the GAuNPs showed
an incremented lectin identification power, at low protein con-
centrations, enabling an easy tool for sugar–lectin recognition.
The glycan–protein interaction has been studied as well em-
ploying surface-enhanced Raman spectroscopy (SERS)
exploiting AuNP ability in amplifying Raman signals [80]. The
greatest advantage in using SERS is the possibility to provide
unique spectral signatures describing glycan–protein interac-
tions. Boons and co-workers prepared label-free microarrays of
lactose-coated AuNPs (diameter of 60 nm) to study lactose
galectin (i.e., galectine 1 and galectin 3) and influenza hemag-
glutinin interactions. The resulting NPs were deposited and
dried on a gold layer and SERS measurements performed.
Finally, partial least squares discrimination analysis (PLS-DA)
was performed to analyze the SERS spectra, differentiating
them in different classes with statistical relevance. Long et al.
[50] developed a simple procedure to analyze in real-time the
carbohydrate–protein interaction at the single NP level, using
for the first time an unusual technique such as the dark field
microscopy, DFM (Figure 3). Briefly, the method is based on
the interaction among 60 nm AuNPs capped with the protein
concanavalin A (ConA, physically adsorbed on the surface) and
smaller dextran-coated AuNPs. ConA-AuNPs, immobilized on
a glass slide, were treated with dextran-AuNPs and when the
two particles interacted, a coupling of the plasmonic oscilla-
tions was detected, resulting in a shift of the statistic peak wave-
length distribution. The statistical analysis of the peak wave-
length was performed starting from the RGB (red, green and
blue) information obtained by DFM by analyzing them with a
self-developed statistical program (nanoparticleAnalysis).
A very interesting result reports on the design of highly stable
carbohydrate-coated gold nanoparticles, able to recognize at
subnanomolar and low picomolar concentrations level of ConA,
wheat germ agglutinin and Ricinus communis agglutinin [43].
In this case, a careful decoration of the gold surface has been
carried out by employing a thio-amphiphilic linker to impart
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Figure 3: The protein–carbohydrate interactions analyzed by conventional dark field microscopy. The interaction among ConA-functionalized AuNPs
(60 nm) and dextran-coated AuNPs (20 nm) are detected by DFM. Reprinted with permission from [50]. Copyright 2015 American Chemical Society.
Figure 4: Copper-free cycloaddition (SPAAC) of azido galactoside on cyclooctyne and schematic depiction of Au surface coating. When galactoside-
coated AuNPs interact with lectin, AuNPs aggregates, inducing a plasmonic band shift. Reprinted with permission from [25]. Copyright 2015 Amer-
ican Chemical Society.
improved solubility and flexibility to the glycosyl-ligand.
UV–vis spectroscopy and dynamic light scattering measure-
ments have been exploited to detect at low picomolar concen-
trations lactose-AuNP, mannose-AuNP and GlcNAc-AuNP
interactions with their cognate lectins. Moreover, by using an
immobilized antibody microarray, it was possible to design a
highly sensitive lectin detection, enhanced by silver addition, by
easy naked eye. Plasmon resonance spectroscopy and naked eye
have been used by Long et al. (Figure 4) to study the interac-
tion of galactoside-AuNPs with peanut agglutinin [25]. In this
case, the glycosyl residue is not coated on the gold surface by
means of a thiol moiety but exploiting the strain-promoted
azide–alkyne cycloaddition (SPAAC) to covalently link an
azido galactoside on a lipid cyclooctyne. In this manner, the
amphiphilic glyco-lipid can be embedded on PEGylated-gold
nanoparticles and the sugar moiety displayed on the outer shell
of the nanosystem is available for interaction with lectin.
In 2016, Sakurai and co-workers [81] combined the multiple
display of the carbohydrate moiety on AuNPs with the photoaf-
finity labeling (PAL), to concentrate and purify proteins by
covalent crosslinking (Figure 5).
Beilstein J. Org. Chem. 2017, 13, 1008–1021.
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Figure 5: A photoaffinity labeling (PAL) approach based on glyco-gold nanoparticles is able to recognize and isolate only the desired protein. After
washing and cleavage steps, the protein can be fully analyzed. Reprinted from [81]. Published by The Royal Society of Chemistry.
Figure 6: Design of the fiber-type “Sugar Chips”. AuNPs are firstly immobilized on an optical fiber functionalized with α-lipoic acid (TA fiber). Succes-
sively, glycosil-thioctic residues were grafted on AuNPs, forming the “Sugar Chips”. Reprinted with permission from [82]. Copyright 2017 American
Chemical Society.
GAuNPs were synthesized by coating the metal surface via
thio-chemistry with a β-D-lactose residue (recognized by a
series of lectins, i.e., PNA or Ricinus communis agglutinin) and
a benzophenone moiety as photoreactive group. GAuNPs were
treated with PNA which cross-linked with the photoreactive
group, affording a PNA-AuNPs complex. The latter was easily
purified by the non-interacting protein via centrifugation and,
eventually, the protein was quantified after an appropriate
cleavage with 2-mercaptoethanol.
A very recent and interesting application showed for the first
time the immobilization of AuNPs on the endface of an optical
fiber by means of thio-chemistry [82]. A second layer of
glycosyl residues (maltose or lactose) containing thioctic acid
was covalently linked on supported AuNPs, affording
the fiber-type “Sugar Chips” (Figure 6). By means of
this sugar chips the carbohydrate−protein interactions
have been analyzed and quantified in a very small
volume with results confirmed by the conventional LSPR bio-
sensors.
Gibson et al. [66] designed 40 nm AuNPs capped with glyco-
PEG ligands to discriminate different strains of E. coli, on the
base of different expression level of the bacterial lectin FimH
with a colorimetric assay. A simple and fast bioassay has been
developed by Lee et al. [83] to recognize cholera toxin (CT), a
protein secreted by the Vibrio cholerae bacterium which is re-
sponsible for cholera disease. A thiol-modified β-galactose de-
rivative was used to coat 10 nm AuNPs and mixed with amino-
terminated quantum dots (CdTe, QD). As a consequence of the
strong hydrogen bonds among QD amines and hydroxy groups
of galactose, a complex of QD-AuNPs occurred as confirmed
by using fluorescence resonance energy transfer (FRET). In the
presence of the analyte (i.e., cholera toxin), galactose-AuNPs
recognize the protein, avoiding the formation of QD complex
and, consequently recovering the fluorescence. This method, al-
Beilstein J. Org. Chem. 2017, 13, 1008–1021.
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though based on a monosaccharide, showed the impressive
improvement obtained for using multivalent glyco-nano-
systems.
Quick serological detection of cancer biomarkers is one of the
main aim in early cancer diagnosis, and GAuNPs seem to be
fundamental in the development of new, cheap and easy tests.
Tian et al. [28] described the design of mannosylated gold
nanoparticles which create a supramolecular glycoprobe in the
presence of a specific mannose-selective Lens culinaria lectin
(LcA). This lectin is particularly interesting because it can have
a strong affinity with the core-fucosylated glycoform of α-feto-
protein (AFP-L3), a recognized biomarker for the diagnosis of
hepatocellular carcinoma. When the glycoprobe interact with a
microplate displaying AFP-L3, LcA strongly bind to AFP-L3
releasing from the supramolecular glycoprobe GAuNPs in a
concentration which can be measured via UV–vis spectroscopy.
Chiodo et al. [84] gave their contribution in the development of
early stage cancer or pathogen diagnosis designing an ELISA
approach to detect anti-carbohydrate antibodies. The innovative
procedure exploited the use of very small AuNPs (2 nm) coated
with tetrasaccharide epitopes of HIV gp120 or tetrasaccharide
epitopes of Streptococcus pneumoniae Pn14PS. The GAuNPs
so obtained were directly coated on commercial ELISA plates
and anti-carbohydrate antibodies were detected in the
nanomolar range both using purified anti-HIV human mono-
clonal antibodies or serum from immunized mice against S.
pneumoniae.
Detection of carbohydrate–influenza virus
interactions
The SERS methodology was extended to the determination of
the binding selectivity for human and avian influenza (H1N1
and H7N9) ,  by  us ing  modi f ied  g lycans  ( lac tose ,
α(2,3)Neu5AcLacNAc and α(2,6)Neu5AcLacNAc) to intro-
duce the active moieties on the gold monolayer. The SERS
spectra registered with changes in the 1400–1600 and
1000–1200 cm−1 bands were indicative of the successful
binding [85]. In this field, a naturally occurring sialylglycopep-
tide extracted from egg yolks was converted into a thiol-termi-
nated molecule and grafted on AuNPs, to develop a gold-based
sensor for influenza virus detection, using both UV–vis spec-
troscopy and dynamic light scattering. Moreover, a selective
detection of the influenza virus can be accomplished. Viral
hemagglutinin (HA) protein, in fact, can bind selectively sialic
acid residues, but the human influenza virus recognizes the
sialic acid α(2,6)galactose sequence while the avian virus recog-
nizes sialic acid α(2,3)galactose chains [85]. GAuNPs functio-
nalized with the exact sequence have been able to selectively
recognize the influenza virus strain by means of a simple colori-
metric assay, observing the hemagglutinin-induced aggregation
of AuNPs [44,45]. Moreover, to improve the sialic residue
display on metal surfaces, Russel and co-workers [45] em-
ployed trivalent α-thio-linked sialic residues as ligands of
AuNPs, confirming the improving ability in binding selectively
the human influenza strain.
Detection of carbohydrate–peptide hormone
interactions
Dextran-coated AuNPs have been employed to investigate the
binding properties of the glucose moiety displayed on a metal
surface with insulin, a peptide hormone [86]. By means of a
UV–vis spectroscopy assay, the authors confirmed the success-
ful use of dextran-coated AuNPs to selectively bind low con-
centrations of insulin (at 1 pM), even in serum samples, and
discovered that the insulin B chain is mainly responsible for the
binding with glucose moiety AuNPs.
Glyco-gold nanoparticles as drug carriers
and contrast agents
Drug nanocarriers play a fundamental role in the development
of nano- and personalized medicine. The main advantages
resulted from the protection of the drug from degradation or
inactivation in vivo, the opportunity to control the drug release
and reduce the systemic toxicity and the exciting chance to
selectively target the damaged tissue. Despite the most common
carriers are based on nano- and microparticles (i.e., albumin,
poly(lactic-co-glycolic acid)-PLGA NPs, liposomes), many ex-
amples in literature report on the development of gold-based
glyco nanoparticles as efficient system to delivery payloads. In
this contest, AuNPs modified with lactose moieties and β-cyclo-
dextrins have been reported by Vargas-Berenguel et al. [87].
The authors showed that GAuNPs were still able to recognize
specific lectin (peanut agglutinin, PNA) and human galectin-3
(Gal-3), exploiting multiple lactose residues displayed on gold
surface. Moreover, due to the presence of the β-cyclodextrin
cavity, these nanostructures worked as site-specific delivery
systems, hosting methotrexate (MTX), an anticancer drug.
The anticancer therapy based on platinum compounds, such as
cisplatin, carboplatin and oxaliplatin, has many positive effects
on the regression of cancer cell proliferation. Unfortunately
these compounds are low tolerated by the organisms, therefore
new metal-based anticancer drugs need to be developed.
Recently, it has been reported the interesting synthesis of
AuNPs coated with glyco-polymers and functionalized with
gold(I) triphenylphosphine (Figure 7) [88]. This work showed
the potentiality of these structures as novel cancer therapeutic
drugs. The glucose and galactose moieties multi-displayed on
gold surface acted as target for asialoglycoprotein receptors,
over-expressed on liver cancer cells, delivering selectively the
anticancer drug Au(I).
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Figure 7: Design of GAuNPs, displaying both sugar residues and the anticancer Au(I)PPh3. Reprinted with permission from [88]. Copyright 2014
American Chemical Society.
In search of novel antimicrobial antigens, chitosan-strepto-
mycin GAuNPs (CA NPs), i.e., carbohydrate-antibiotic conju-
gates, were prepared and resulted able to overcome antibiotic
resistance of microbial biofilms, since CA NPs render strepto-
mycin more accessible to biofilms, thereby more available to
interact with biofilm bacteria [89]. Similarly, a novel recyclable
E.coli-specific killing GAuNP nanocomposite, carrying either a
targeting agent towards E. coli pili and an antibacterial polymer,
resulted able to bind E. coli specifically and to kill the attached
bacteria, by enhancing the local concentration of biocidal agent
on the bacterial surface [90].
GAuNPs find interesting application also in the treatment of
HIV infection. β-D-Glucose coated AuNPs have been deco-
rated with the antiviral drugs abacavir (ABC) and lamivudine
(3TC) and used as delivery systems. These co-drug structures
were able to release the drugs in acidic conditions to inhibit
viral replication in cellular assays [91].
GAuNPs represent a promising candidate for developing thera-
nostic agents, able to carry drugs to a selected tissue and to act
as a sensitive probe. In fact, the metallic core of GAuNPs has
been exploited to design and develop promising early detecting
agents of cancer or inflammation. In this contest, Andresen and
co-workers produced a nanogel injectable in humans to detect
cancer cells. The nanogel was composed by sucrose acetate
isobutyltyrate (SAIB) and poly(N-isopropylacrylamide)
(PNIPAM)-coated AuNPs, compatible with SAIB matrix. The
nanogel had good opacity for 2D X-ray visualization and was
tested in vivo in immunocompetent healthy NMRI-mice and in
humans [92]. The gold high X-ray absorption and a carbo-
hydrate coating have been also exploited by Polito and
co-workers to produce functional X-ray contrast agents based
on glucosamine-coated AuNPs [22]. By micro-CT analysis per-
formed on lung injured mice, the authors demonstrated that
GAuNPs selectively targeted overexpressed glucose receptors
(GLUT1) and accumulated in the damaged lung, while PEG-
ylated AuNPs did not show any relevant accumulation in the
inflammation site. Moreover, another study on the synthesis of
glucose-functionalized AuNPs demonstrated that GLUT1-
targeting GAuNPs are well compatible with blood and do not
significantly interact with ovine red blood cells [93]. In the last
years, numerous compounds containing Gd3+ have been de-
veloped and used as magnetic resonance imaging (MRI)
contrast agents. Recently, gold based nanosystems containing
Gd3+ were developed. Arus et al. described the synthesis of
water dispersible GAuNPs decorated with Gd complexes [94].
The glyco-shell conferred to the nanotracer a targeting proper-
ties while Gd3+ acted as MRI contrast agent. The authors settled
an ex vivo experiment which let them to use small amounts of
contrast agent (5 nmol/animal), avoiding toxicology and in vivo
test. Moreover, GAuNPs showed their extreme versatility in a
very interesting paper reported by Penadés and collaborators
[11]. They design GAuNPs able to pass the brain blood barrier
(BBB) of healthy mice and give images of intact brain. AuNPs
were decorated in a controlled ratio with glucose, neuropep-
tides and a chelator of gallium-68, a sensitive positron emission
tomography (PET) tracer, affording the quantification of BBB
permeability in healthy small animals.
Glyco-gold nanoparticles in immunology
The development of nanoparticle-based strategies for the modu-
lation of the immunosystem represents one of the biological and
biomedical applications of nanomaterials. Nanoparticle technol-
ogies offer the possibility of new approaches to tune specific
immune responses for prevention or treatment of diseases.
These approaches are inspired by the availability of novel nano-
materials with specific capabilities [95]. AuNPs have attracted
great attention in this field due to their unique characteristics of
biocompatibility and easy fabrication, already outlined previ-
ously. In the last five years, significant examples on the use of
carbohydrate-coated GAuNPs in the field of immunology have
been reported, addressing different possibilities of intervention
on the immune system.
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GAuNPs and activation of the immune system via
cellular targeting
Glycan-conjugated globular shaped nanoparticles have a higher
surface area to volume ratio in comparison to other glycoclus-
ters, i.e., glycolipid micelles and glycoproteins, which allows an
ordered, controlled and stable tridimensional presentation of the
ligands, providing higher ligand binding capacity [6,96]. For
this reason, they represent an ideal scaffold to study the activa-
tion of the immune system in response to pathogens mediated
by lectins, like DC-SIGN. Mammalian cell surface lectins,
expressed on the surface of dendritic cells (DC) and macro-
phages, recognize in a multivalent way a vast array of glycans
on the exterior of pathogens. Natural carbohydrate ligands
include high-mannose N-glycans, such as those found on the
HIV gp120 protein, and Lewis-type glycans. Ligand recogni-
tion often initiates events which are able to trigger specific
signaling and result in a robust immune activation in humans.
For example, galactofuranose (Galf) functionalized AuNPs
were found able to elicit a pro-inflammatory response in
dendritic cells via interaction with the lectin DC-SIGN, as indi-
cated by the up-regulation of several maturation markers and in-
creased secretion of pro-inflammatory cytokines interleukin 6
(IL-6) and tumor necrosis factor α (TNF-α) [97]. These data in-
dicate that a multivalent system of Galf, a five-membered form
of galactose found in nonmammalian pathogenic species, i.e.,
the fungus Aspergillus, is able to modulate the innate immune
response via dendritic cells, suggesting Galf-GNPs as versatile
tools in functional studies to address the role of Galf in host-
pathogen interaction.
DC-SIGN targeting through GAuNPs has also been exploited
differently in a study on GAuNPs functionalized with
α-fucosylamide, an efficacious synthetic DC-SIGN ligand, ana-
logue of the natural fucose-containing Lewisx trisaccharide
[98]. This paper shows that GAuNPs bearing 50% of fucosyl-
amide are able to compete with the natural gp120 ligand on
DC-SIGN expressing cells, and to promote DC-SIGN internal-
ization. On the contrary, the GAuNPs lack any immunomodula-
tory activity, and do not induce DC maturation or trigger
cytokine responses. Thus, in this example, GAuNPs,
can be considered as vehicles, neutral carriers, to target anti-
gens to DCs via lectins, a well-known strategy explored in
immunotherapy.
GAuNPs in vaccine development
AuNPs engineering is offering significant contribution to
immunology also in vaccine development. The repetitive
antigen display is the key point related to this nanotechnology-
based approach, which aim to trigger the production of specific
and functional antibodies that prevent initial infection limiting
pathogen/viral dissemination. Recent publications suggest that
many different aspects are becoming clear and have to be
underlined.
The design of anti HIV-1 vaccines depends on the identifica-
tion of sugar epitopes of the surface envelope glycoprotein of
HIV-1, capable of eliciting a protective response. GAuNPs
coated with high-mannose type oligosaccharide of HIV-1
gp120, were prepared as glycoconjugate systems able to mimic
the natural presentation of gp-120 high-mannose glycans. It was
demonstrated that they were able to inhibit DC-SIGN-mediated
HIV-1 infections and to interfere with the antibody/gp120
binding process. Most of these systems proved able to elicit the
production of carbohydrate-specific antibodies in animals,
though the generated IgGs turned out to be unable to neutralize
the virus. More recently, the Man9GlcNAc2 was identified as a
conserved motif on the HIV surface: this result stemmed from
the observation that partial structures of this glycan could be
recognized by broadly neutralizing antibodies, found in infected
patients. These data suggested the use of these self-glycans for
the design of effective vaccine and inspired the preparation of
new generation GAuNPs, coated with synthetic partial struc-
tures of Man9 multimerized on the same GAuNP, which provi-
ded better binding to the anti-HIV antibody 2G12 compared to
GAuNPs carrying only one individual oligomannoside [99].
This result, based on the assembly of “antennas” on the NP sur-
face, shows that the cluster presentation of the gp120 high-
mannose type glycan on GAuNPs provides different binding
modes and hence more opportunities to mimic the multivalent
interaction between the antibody and the saccharide. Finally,
these results represent a solid support for the design of new and
more effective nanoparticles based systems.
A different approach towards the development of a synthetic
HIV vaccine candidate based on GAuNPs, exploit the glyco-
nanosystem as a tool which modulate and control the biologi-
cally active conformation of a significant epitope [100]. In this
respect, negatively charged GAuNPs were conjugated to the
third variable region (V3 peptide) of the HIV-1 gp120. The V3
peptide is a major immunogenic domain of HIV-1, which can
be exploited as a candidate for anti-HIV vaccine development,
given that the immunologically active conformation is
conserved. The peptide on the nanoparticle showed increased
stability towards degradation as compared to the free peptide.
Moreover, V3β-GAuNPs elicit antibodies in rabbits that recog-
nize a recombinant gp120, even in the absence of highly
immunogenic proteins.
Another example on the importance of the way in which glyco-
conjugates are presented through NPs, regards the design and
construction of GAuNPs decorated with mucin-related glycans
for cancer immunotherapy [57]. A monomolecular sugar
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coating do not represent well the structure of mucin glyco-
protein on the surface of cancer cells, which are characterized
by a dense presentation of glycans attached to a protein back-
bone. So, multicopy–multivalent polymeric versions of the
tumor-associated α-GalNAc (Tn) antigen, obtained through
RAFT polymerization, were prepared and used to prepare
GAuNPs with a surface that mimics much more closely the sur-
face of cancer cells. These systems were able to generate a sig-
nificant immune response in vivo, with the generation of
detectable levels of antibodies specific for naturally occurring
mucin glycans, without the need for a immunogenic protein
component.
In a different example, Barchi and co-workers focused on the
Thomsen Friedenreich tumor-associated antigen (TFag) and
synthesized TFag-amino acid-coated AuNPs by means of a
thiol-polyethylene glycol spacer. Among the synthesized
GAuNPs, TFag-Thr-AuNPs showed, in vitro, an increased cyto-
toxic activity toward lymphoma cells, resulting active at a very
low micromolar range [101]. With the aim to activate the
human immune system against self-tumor cells, Schlecht and
co-workers designed the synthesis of AuNPs functionalized
with Mucin1(MUC1)-glycopeptide antigens [102]. Mucins are a
family of glycosylated proteins with a high molecular weight,
produced by epithelial tissues. The most studied is the mem-
brane-bound glycoprotein MUC1, a glycoprotein with exten-
sive O-linked glycosylation in its extracellular domain. The
authors demonstrated that the multivalent presentation of
MUC1-glycopeptide antigens were able to stimulate the
immune system, suggesting GAuNPs are interesting platforms
for developing new immunotherapeutics.
The potential of AuNPs as antigen carriers for the development
of synthetic vaccines is still being investigated in the context of
bacterial infections. NPs are indeed promising vector systems to
explore vaccination against infectious diseases.
Recently, a study on the identification of an optimal vaccine
formulation to protect against listeriosis, proposed the use of
GAuNPs loaded with glucose and the LLO91-98 Listeria peptide
antigen as a system to target DCs, since Listeria protection is
largely dependent on T-cells activation [103]. The presence of
glucose ensures a biocompatible and water dispersible highly
efficacious DC targeting system. DC loaded in vitro with
GAuNPs-LLO, co-formulated with an adjuvant, provided better
protection against listeriosis than DC loaded in vitro using free
LLO peptide, and induced LLO-specific T-cell immunity and
protection against Listeria. The system was effective in mice
immunization either using a DC vaccine or a standard immu-
nization approach. The data were followed by a study on preg-
nant mice vaccination which demonstrated the ability of this
AuNP based vaccine system to protect neonates born to vacci-
nated mothers from the bacteria [104].
In another study, the impact of multivalency on the ability of
GAuNPs to induce immune cell responses in vitro was studied
using highly pure NPs coated with non-immunoactive mono-
and disaccharides related to the capsular polysaccharide of
serogroup A of Neisseria meningitides [53]. The results showed
that the systems were able to activate the antigen-presenting
cells, to induce the releasing of effector functions of the same
cells and to stimulate T cell proliferation, but highlighted that
immunoactivity is strongly dependent on the size of the nano-
particle (larger NPs, 5 nm, performed better than smaller ones,
2 nm) and on the length of the saccharide fragment. There is
growing evidence that the shape and size of the AuNPs affect
immunological responses in vitro and in vivo [105].
In another recent study on the development of synthetic nano-
systems as potential carbohydrate-based vaccine, GAuNPs were
loaded with synthetic oligosaccharide fragments corresponding
to the repeating units of S. pneumoniae (Pn) CPS type 19F and
14 [106]. This new approach has explored the effect of the pres-
ence of two different saccharide epitopes from diverse bacterial
serotypes simultaneously displayed onto the NP surface on the
immunological response. Mice immunization showed that the
concomitant presence of Pn14 and Pn19F repeating unit frag-
ments on the same NP critically enhance the titers of specific
IgG antibodies towards type 14 polysaccharide compared with
GAuNP exclusively displaying Pn14.
The GAuNP technology has also been applied in the regulation
of important genes of the apoptotic pathway. New GAuNP
systems displaying cMyc targeting siRNA resulted capable of
inducing apoptosis via hyperactivation of cell death receptors
and caspase pathways [107].
Conclusion
Glyco-gold nanoparticles represent one of the most versatile,
exciting and promising hybrid nanosystems. Combining the vast
properties of the noble metal at its nano-size with the funda-
mental biological role covered by carbohydrates, GAuNPs hold
great potentiality in bio-nanomedicine. In this review, we have
attempted to summarize the last results obtained in this field,
anticipating the numerous applications with a detailed descrip-
tion and implication of each part of the hybrid system. A careful
GAuNP design must take into consideration all the parameters
which characterize the final glyco-nanoparticle. Well planned
GAuNPs offer a unique chance to researchers to mimic the
nature’s glycocalix and to explore the world of weak carbo-
hydrate interactions, opening the way to innovative diagnostic
tools or new therapeutic or theranostic agents.
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